Goldenwell Biotech (GWLL) Debt to Equity (2023 - 2025)
Goldenwell Biotech (GWLL) has disclosed Debt to Equity for 3 consecutive years, with -$1.17 as the latest value for Q1 2025.
- For the quarter ending Q1 2025, Debt to Equity changed N/A year-over-year to -$1.17, compared with a TTM value of -$1.17 through Mar 2025, changed N/A, and an annual FY2024 reading of -$2.02, down 326.79% over the prior year.
- Debt to Equity was -$1.17 for Q1 2025 at Goldenwell Biotech, up from -$2.02 in the prior quarter.
- Across five years, Debt to Equity topped out at $0.89 in Q4 2023 and bottomed at -$2.02 in Q4 2024.
- Average Debt to Equity over 3 years is -$0.77, with a median of -$1.17 recorded in 2025.
- Peak annual rise in Debt to Equity hit 326.79% in 2024, while the deepest fall reached 326.79% in 2024.
- Year by year, Debt to Equity stood at $0.89 in 2023, then plummeted by 326.79% to -$2.02 in 2024, then skyrocketed by 42.12% to -$1.17 in 2025.
- Business Quant data shows Debt to Equity for GWLL at -$1.17 in Q1 2025, -$2.02 in Q4 2024, and $0.89 in Q4 2023.